• Publications
  • Influence
Novel 18F-Labeled Arylquinoline Derivatives for Noninvasive Imaging of Tau Pathology in Alzheimer Disease
Neurofibrillary tangles in Alzheimer disease (AD) brains are composed of the microtubule-associated protein tau. Noninvasive monitoring of tau protein aggregates in the living brain will provideExpand
  • 218
  • 10
18F-THK5351: A Novel PET Radiotracer for Imaging Neurofibrillary Pathology in Alzheimer Disease
Imaging of neurofibrillary pathology in the brain helps in diagnosing dementia, tracking disease progression, and evaluating the therapeutic efficacy of antidementia drugs. The radiotracers used inExpand
  • 177
  • 8
Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain
Background18F-THK5351 is a quinoline-derived tau imaging agent with high affinity to paired helical filaments (PHF). However, high levels of 18F-THK5351 retention in brain regions thought to containExpand
  • 143
  • 7
Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET.
Non-invasive imaging of tau pathology in the living brain would be useful for accurately diagnosing Alzheimer's disease, tracking disease progression, and evaluating the treatment efficacy ofExpand
  • 187
  • 5
In vivo visualization of tau deposits in corticobasal syndrome by 18F-THK5351 PET
Objective: To determine whether 18F-THK5351 PET can be used to visualize tau deposits in brain lesions in live patients with corticobasal syndrome (CBS). Methods: We evaluated the in vitro binding ofExpand
  • 66
  • 4
The challenges of tau imaging
In vivo imaging of tau pathology will provide new insights into tau deposition in the human brain, thus facilitating research into causes, diagnosis and treatment of major dementias, such asExpand
  • 71
  • 4
In vivo evaluation of a novel tau imaging tracer for Alzheimer’s disease
PurposeDiagnosis of tauopathies such as Alzheimer’s disease (AD) still relies on post-mortem examination of the human brain. A non-invasive method of determining brain tau burden in vivo would allowExpand
  • 133
  • 3
Longitudinal Assessment of Tau Pathology in Patients with Alzheimer’s Disease Using [18F]THK-5117 Positron Emission Tomography
The formation of neurofibrillary tangles is believed to contribute to the neurodegeneration observed in Alzheimer’s disease (AD). Postmortem studies have shown strong associations between theExpand
  • 51
  • 3
Tau imaging with [18F]THK‐5351 in progressive supranuclear palsy
Visualization of pathogenic protein aggregates is crucial to elucidate pathomechanisms and to make an accurate diagnosis in many neurodegenerative conditions. Aggregates of the microtubule‐bindingExpand
  • 52
  • 3
Assessing THK523 selectivity for tau deposits in Alzheimer’s disease and non–Alzheimer’s disease tauopathies
IntroductionThe introduction of tau imaging agents such as 18F-THK523 offers new hope for the in vivo assessment of tau deposition in tauopathies such as Alzheimer’s disease (AD), where preliminaryExpand
  • 59
  • 3